Fremanezumab is a fully humanized monoclonal antibody directed against calcitonin gene-related peptides (CGRP) alpha and beta.[9] The precise mechanism of action is unknown.[2] It is the only approved anti-CGRP monoclonal antibody that can be given with a quarterly interval.